Pulmonary hypertension (PH) adds a substantial disease burden, including higher mortality, when associated with interstitial lung disease (ILD), a severe, chronic, progressive condition...

This retrospective study was conducted to evaluate all-cause healthcare resource utilization (HCRU) and costs in commercially insured patients living with pulmonary arterial hypertension (PAH) and explore end-of-life (EOL)-related HCRU and costs.

Data on demographic characteristics and therapeutic approaches in Latin American pulmonary arterial hypertension (PAH) patients are scarce.

Parameters of cardiopulmonary exercise testing significantly discriminate between healthy subjects and patients with pulmonary hypertension (PH), also according to the new 2022 definition of pulmonary hypertension (mean pulmonary arterial pressure mPAP > 20 mmHg).

Pulmonary hypertension (PH) is associated with adverse outcomes in chronic kidney disease (CKD) patients.

This article examines technical use of Fitbit during an intervention for pulmonary hypertension (PAH)-patients.

A blood test identifying patients at increased risk of pulmonary hypertension (PH) could streamline the investigative pathway...

Prostacyclin therapy is a mainstay of the management of pulmonary arterial hypertension (PAH).

Pulmonary arterial hypertension (PAH, or PH Group 1), a disease of aberrant pulmonary vascular remodeling, causing progressive right heart failure (RHF) due to elevation of pulmonary vascular resistance (PVR).